anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The efficacy of FENSOLVI was evaluated in an uncontrolled, open-label, single arm clinical trial in which 64 pediatric patients (62 females and 2 males, naïve to previous GnRH agonist treatment) with CPP received at least one dose of FENSOLVI at a dosing interval of 24 weeks and were observed for 12 months. The mean age was 7.5 years (range 4 to 9 years) at the start of treatment. In pediatric patients with CPP, FENSOLVI reduced stimulated and basal gonadotropins to prepubertal levels. Suppression of peak stimulated LH concentrations to <4 IU/L was achieved in 87% of pediatric patients by month 6 and in 86% of patients by month 12. Suppression of estradiol or testosterone concentration to prepubertal levels at the 6-month assessment was achieved in 97% and 100% of patients, respectively. Suppression of estradiol or testosterone was maintained at the 12-month assessment with 98% (55/56 females) and 50% (1/2 males) maintaining suppression. FENSOLVI arrested or reversed progression of clinical signs of puberty with reductions in growth velocity and bone age. Mean growth velocity decreased from 8.9 ± 13.1 cm/yr at 1 month to 6.9 ± 3.1 cm/yr at 6 months and to 6.4 ± 1.9 cm/yr at 12 months. 

Table 3: Reproductive Hormone Levels in Pediatric Patients with CPP Treated with FENSOLVI 45 mg Every 6 Monthsa

Eight female patients out of 62 did not meet the primary efficacy criteria for LH <4 IU/L at 6 months. In four of the eight patients, the LH level at 6 months was between 4.2 and 4.8 IU/L. The remaining four patients had LH levels >5 IU/L. However, post stimulation estradiol was suppressed to prepubertal levels (<20 pg/mL) in seven of the eight patients at month 6 and was maintained through month 12.
PURPOSE: E-textiles have been the focus of interest in health technology, but little research has been done so far on how they could support persons with complex communication needs. A global estimate is that 97 million people may benefit from Augmentative and Alternative Communication (AAC). Unfortunately, despite the growing body of research, many persons with complex communication needs are left without functional means to communicate. This study aimed to address the lack of research in textile-based AAC and to build a picture of the issues that affect novel textile-based technology development.
MATERIALS AND METHODS: We arranged a focus group study for altogether 12 speech and language therapists to elicit user scenarios to understand needs, activities, and contexts when implementing a novel, textile-based technology in a user-centred approach.
RESULTS AND CONCLUSION: As a result, we present six user scenarios that were created for children to enhance their social interaction in everyday life when using textile-based technology that recognizes touch or detects motion. The persistent availability and the individual design to meet a person's capability along with ease of use and personalization were perceived important requirements. Through these scenarios, we identified technological constraints regarding the development of e-textile technology and its use in the AAC field, such as issues regarding sensors and providing power supply. Resolving the design constraints will lead to a feasible and portable e-textile AAC system.
This invention provides distillation technique of obviously anti tumor active compound in white bloom herba patriniae, it is (2S)-5, 7, 2', 6'-tetrahydroxy-6, 8-di (gama, gama-dime- thylallyl)-flavanone. It includes crude distilling substance distillation, crude distilling substance polar subsection, silica gel column chromatography three procedures. Its features are that the crude substance is got by using ethanol distilling botanical, organic solvent is used to subsection extracte the crude substance, and then pure product is got after silica gel column chromatography. The preparation quantity is large in this invention, product purity is high (the purity is more than 99 percent). Anti tumor active filtration is also done to validate its anti tumor activity. The compound can be used in preparing anti tumor medicine aspect.
The pivotal role of TL1A in modulating immune pathways crucial for inflammatory bowel disease (IBD) and intestinal fibrosis offers a promising therapeutic target. Phase 2 trials (TUSCANY and ARTEMIS-UC) evaluating an anti-TL1A antibody show progress in expanding IBD therapeutic options. First-in-human data reveal reduced expression of genes associated with extracellular matrix remodeling and fibrosis post-anti-TL1A treatment. Investigational drug TEV-48574, potentially exerting dual antifibrotic and anti-inflammatory effects, is undergoing a phase 2 basket study in both ulcerative colitis (UC) and Crohn disease (CD). Results are eagerly awaited, marking advancements in IBD therapeutics. This critical review comprehensively examines the existing literature, illuminating TL1A and the intricate role of DR3 in IBD, emphasizing the evolving therapeutic landscape and ongoing clinical trials, with potential implications for more effective IBD management.
PURPOSE: A pharmaceutical composition and a health food containing crude drug extract for preventing and treating depression are provided to significantly suppress oxidative stress or neurotoxicity and to prevent and treat depression and anxiety. CONSTITUTION: A pharmaceutical composition for preventing and treating depression contains extract of Cyperus rotundus L., Poria cocas(Schw.) Wolf., Glycyrrhiza ssp., and Coptis chinensis. The extract is prepared by extracting with water, low carbon number alcohol of 1-4 carbon atoms, or a mixture thereof. The pharmaceutical composition is manufactured in the form of granules, lemonades, powder, syrups, liquids, elixirs, liquid extracts, emulsions, suspensions, tablets, or pills. [Reference numerals] (AA) Control group; (BB) Non-administered; (CC) Experimental group
A high throughput neurophysiological assay for identifying anti-psychotic compounds is disclosed. In particular, a high throughput neurophysiological assay using information obtained from injecting a neural activity blocker, such as tetrodotoxin (TTX), into one hippocampus persistently coactivated pyramidal cells in the uninjected hippocampus that initially discharged independently. In accord with the definition of cognitive disorganization, pyramidal cell firing rates only changed for 15 min and did not accompany the coactivation. The disclosed assay uses the TTX-induced coactivity of hippocampal pyramidal cell discharge to identify compounds that may prevent or attenuate the changes in the hippocampal pyramidal cell discharge observed when a neural activity blocker is administered. The assays of the invention are useful for high throughput screening of targets in the discovery of drugs that have anti-psychotic properties. Also disclosed is a method of inducing and measuring neural activity normally associated with a psychotic state.
PURPOSE OF REVIEW: Bladder pain syndrome/interstitial cystitis (BPS/IC) is a common medical problem in both sexes affecting people of all ages. Patients might report overactive bladder symptoms with additional bladder pain at maximum bladder filling, during and after micturition. This review aims to highlight pathophysiological mechanisms associated with this disease.
RECENT FINDINGS: Latest literature exposes different pathophysiological mechanisms such as impaired urothelial barrier function, alteration of urothelial factors and cytokines, chronic inflammation, vascular lesions, neurogenic inflammation and processes in the central nervous system leading to central sensitization. According to the involved mechanisms, BPS/IC may be arranged in clusters according to the clinical phenotype thus helping in clinical decision-making and treatment. Moreover, patients with BPS/IC suffer from other comorbidities such as fibromyalgia, irritable bowel syndrome, chronic pain and functional syndromes and psychosomatic diseases making the management challenging for medical professionals.
SUMMARY: Bladder pain syndrome/interstitial cystitis is a complex heterogeneous medical condition involving different pathomechanisms leading to bladder pain and dysfunction, consequently, impairing quality-of-life in affected individuals. However, these mechanisms are still not fully understood, so that patient treatments often remain unsatisfactory. For this reason, continuing research is important to understand the underlying pathomechanisms to discover biomarkers and treatment targets eventually improving diagnostic and therapeutic measures of BPS/IC.
Pregnant patients meeting Center for Disease Control (CDC) guidelines for anemia during pregnancy will be screened for participation in the study. In the outpatient setting at our institution it is standard of care that these women have complete blood counts (CBCs) drawn every 4-6 weeks. At the time of the routine blood draw, we will place the non invasive monitor on their finger to record the hemoglobin value. We will be comparing the hemoglobin values obtained from the CBC to that obtained from the non-invasive monitor.
SMA is a neuromuscular disorder characterized by degeneration of spinal cord motor neurons and muscular atrophy. SMA is classified into three clinical subtypes according to the severity and age of onset (Types I, II and III). Type II (intermediate) SMA has its onset in early childhood (prior to 18 months) and is characterized by the failure to stand or walk unassisted. Individuals with Type III SMA (mild SMA or Kugelberg-Welander disease) typically develop symptoms after 18 months of age and display a wide range of clinical heterogeneity. The clinical spectrum ranges from rapid progressive weakness resulting in wheelchair dependence in late childhood to patients being able to walk in adult years and living productive and independent lifestyles for the majority of their lives.

In our laboratory, our preliminary results indicate that HU treatment significantly increases both SMN mRNA expression and intact SMN protein levels in vitro. These data confirm previous observations that in vitro treatments of SMA lymphocytes with hydroxyurea resulted in augmentation of the SMN2 gene expression in a dose and time related manner. Based on these exciting pre-clinical data, coupled with the well-documented side-effect profile of HU in children, we are conducting a pilot clinical trial using HU in children with Types II and III SMA. This clinical trial study is intended to establish the safety profile in children with Types II and III SMA; to identify reliable outcome measures; and to detect the possible clinical efficacy of HU treatment in children with Types II and III SMA.
It was a parallel designed single blinded randomized controlled trial conducted in the Green Poly Clinic Bahria town, Lahore, Pakistan using non probability convenient sampling. patients who met eligibility criteria was informed about the aim of study. consent form were signed by all participants.After baseline assessment ,participants were randomly assigned in two groups.(ratio 1:1) The calcualted sample size was 27 in each group. i.e. 54 ( 27 in each group). After adding 20% drop out the final size will become, 64( 32 in each group) using 95% level of significance and 80% power of study.
A method uses Smad for cancer treatment by expressing Smad in solid malignant tumor cells. An adenovirus expression vector includes the Smad4 or Smad3 gene. An adenovirus can produce Smad4 or Smad3 protein within cells by using the above expression vector. A preparation method includes a selection process of RCV-negative clone from adenovirus clones obtained by amplification in packaging cells infected with the adenovirus expression vector and adenovirus mother vector. A method uses the above adenovirus for cancer treatment whereby Smad4 or Smad3 is expressed in solid malignant tumor cells by infecting the cells with adenovirus including Smad. Gene therapy for cancer using Smad treats solid malignant tumors without side effects.
Patients receive leucovorin calcium IV and fluorouracil (5-FU) IV on days 1-5 of courses 1, 3, and 4. Courses repeat every 28 days. During course 2, patients undergo radiotherapy 5 days a week and receive 5-FU IV continuously for 5 to 6 weeks. Patients rest for 28-35 days between course 2 and 3.
Apparatus, implanted subcutaneously or in muscle, fat, joint spaces, or body cavities of any type, detects and responds to an allergic and/or anaphylactic reaction. Detection is carried out by monitoring the levels of biomarker molecules that indicate the occurrence of an allergic and/or anaphylactic reaction, such as: histamine, leukotrienes, prostaglandins, cytokines, tryptase, Fc-ε-RI complexes, anaphylatoxin C3a, chymase, carboxypeptidase A, platelet-activating factor 8 , other mast cell degranulation byproducts, or other basophil activation compounds. An appropriate dosage of medication (such as epinephrine, antihistamines, or steroids) is automatically dispensed to mitigate the allergic/anaphylactic response. The simplicity and ease of use of the invention has the potential to save many lives worldwide, while dramatically mitigating the risks of the current methods of handling severe allergic reactions using external auto-injectors.  8  Sala Cunill, A., Cardona, V. Biomarkers of anaphylaxis, beyond tryptase.  Current Opinion in Allergy and Clinical Immunology . Vol 15(4), August 2015, p 329-336. Doi: 10.1097/ACI.0000000000000184.
Pyridylalkyl nitrates of formula (I) and their salts are prepd. by reacting a cpd. of formula (II) or its reactive deriv. with a nitrating agent. In the formulas, Ra1= H, lower alkyl or hydroxy (lower)alkyl; one of Ra2 and Ra3 is mono- or dihydroxy (lower)alkyl and the other is H or halogen; R1 is H, lower alkyl, halogen or nitroxy (lower)alkyl; one of R2 and R3 is mono- or dinitroxy (lower) alkyl and the other is H or halogen. (I) are vasodilators, useful for treatment of coronary insufficiency, angina pectoris or myocardial infarction.
1387306 Derivatives of 3,4-diphenylpyrazolyl- 5-acetic acid SOC GENERALE DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES 14 March 1973 [15 March 1972] 12182/72 Heading C2C The novel 3,4-diphenylpyrazolyl-5-acetic acid derivatives of general Formula I wherein R 1  and R 2  are independently phenyl groups optionally substituted by halogen, CF 3 , C 1-4  alkyl or C 1-4  alkoxy groups; R 3  is a straight or branched chain C 3-7  alkyl or alkenyl group or a phenyl or benzyl group which is optionally ring substituted by halogen, CF 3 , C 1-4  alkyl or C 1-4  alkoxy groups or by any two of these substituents; R 4  is H or C 1-4  alkyl and A is -CO 2 H, CO 2 R 5  or CONR 6 R 7  where R 5  is a C 1-4  alkyl or benzyl group and R 6  and R 7  are H or C 1-4  alkyl or R 6 -N-R 7  represents a pyrrolidino, piperidino or morpholino group, may be prepared by (a) hydrolysing a compound of Formula II  in which R 1 , R 2 , R 3  and R 4  are as above and Z is an ester, nitrile, amide or thioamide group or (b) decarboxylating a malenic acid derivative of general Formula III in which R 1 , R 2 , R 3  and R 4  are as defined above or (c) by reaction of a 1,2-diphenyl acetylene with a sydnone of Formula V wherein Y represents or -COCH 3 . Ethyl-N-benzylaminoacetate is prepared by reaction of benzylamine with ethyl bromoacetate and is further reacted with sodium nitrile and concentrated hydrochloric acid to form ethyl-N- nitrosobenzylaminoacetate which is, in turn, reduced with zinc and acetic acid to obtain ethyl-1-benzylhydrazinylacetate. Reaction of this product with benzil yields ethyl-α-benzylbenzylidene-N-benzoylhydrazinyl acetate which is cyclized on treatment with sodium ethylate to obtain ethyl-1-benzyl-3,4-diphenylpyrazole-5-carboxylate. Reduction of this carboxylate with LiACH 4  yields 1-benzyl-3,4-diphenyl-5-hydroxymethylpyrazole which is reacted with thionyl chloride to obtain 1-benzyl-3,4-diphenyl-5- chloromethylpyrazole which is in turn reacted with sodium cyanide to obtain 1-benzyl-3,4- diphenylpyrazole-5-acetonitrile. Using the same process steps 1-isobutyl-3,4- diphenylpyrazole-5-acetonitrile and 1-phenyl- 3,4-diphenylpyrazole-5-acetonitrile are prepared respectively from isobutylamine and aniline. Methyl-N-isobutyl-#-aspartate is prepared by reacting monomethyl maleate with isobutylamine and is then reacted with sodium nitrite and conc. hydrochloric acid to obtain methyl-N- isobutyl-N-nitroso-#-aspartate which is reacted with perchloric acid to obtain methyl-3-isobutyl- 4-sydnonyl acetate. α - [1 - Benzoyl - 3,4 - diphenylpyrazolyl - 5]- propionitrile is prepared by reacting 1-benzyl- 3,4 - diphenylpyrazolyl - 5 - acetonitrile with methyl iodide in the presence of NaNH 2 . Pharmaceutical compositions having antiinflammatory and antipyretic activity for oral or rectal administration comprise a compound of Formula I optionally together with a pharmaceutical adjuvant and standard pharmaceutical media and diluents.
The utility model is a black plaster with intermediate net fabric which is of a black plaster layered structure, in particular to the black plaster with gridding layer of netted holes in the flesh layer of the plaster. The black plaster consists of a back-up surface and a plaster flesh and is characterized in that: the plaster flesh is of the gridding layer of netted holes. The utility model enables the layer in-between structure of the black plaster to be more reasonable and scientific, while maintaining the composition and content of the existing black plaster to be unchanged, so as to enhance the flowing resistance inside the plaster flesh, and reduce the mobility. In this way, the plaster is stably placed on the affected area and the medical effectiveness of the black plaster can be normally displayed. In addition, the gridding layer can absorb the plaster flesh and prevents the plaster flesh from spreading to avoid the surrounding skin and cloth being contaminated; the gridding layer and the plaster flesh on the external; side are connected through the holes. The medical effectiveness and the thickness of the black plaster flesh is the same with that of the existing plaster flesh. Because of the simpleness in operation and convenience in carrying out, the utility model can be widely promoted.
Gelatin beadlets comprising a readily oxidisable material, e.g. a vitamin, are prepared by forming an aqueous emulsion containing the said substance and gelatin, forming discrete droplets thereof above the surface of a vegetable oil, allowing the droplets to fall through an inert atmosphere into the oil, which is maintained at a temperature within the range 15-25 DEG C., cooling the oil containing the droplets to a temperature within the range 0-15 DEG C. and dehydrating the gelatin beadlets thereby formed, e.g. by washing with a dehydrating solvent and heat (35 DEG C.) or vacuum.  The emulsion formed preferably contains oil-soluble and water-soluble antioxidants and a sugar, particularly invert sugar.  Specified readily oxidizable substances are fat-soluble vitamins, e.g. vitamin A and esters thereof, vitamins D, E and K and carotene.
FIELD: medicine. ^ SUBSTANCE: invention relates to field of medicine. Antibacterial medication represents suspension of colloidal silver in water, containing cationic surface -active substance or mixture of such substances. Antibacterial medicine is obtained in the following way: to water solution of silver salt with intensive mixing added is solution of, at least, one cationic surface-active substance and solvent. ^ EFFECT: invention insures wide spectrum of antibacterial action. ^ 11 cl, 8 dwg
Participants randomized into the Intensive BP arm will have a goal of SBP \<120 mm Hg. 2-drug therapy initiated in most Intensive participants; age ≥75 years and SBP 130-139 mm Hg on 0-1 drug; may begin with 1 drug, but add second at 1 month if SBP ≥130 mm Hg; drugs added and/or titrated at each visit (monthly) to achieve SBP \<120 mm Hg; at periodic "milepost" visits: addition of another drug "required" if not at goal.
<P>PROBLEM TO BE SOLVED: To provide a communication system that can recognize the types of exercises that users do even in areas for exercises using no exercise equipment in exercise facilities.  <P>SOLUTION: The communication system includes a first communication device 10 that a user who uses divided areas dividing a particular area wears, a plurality of second communication devices 20 installed over the particular area, and a management apparatus 40. The first communication device 10 includes a first communication device control means 16 for transmitting first identification information to the second communication devices. The second communication devices 20 each include a second communication device control means 24 for transmitting the first identification information with second identification information attached to the management apparatus. The management apparatus 40 includes an area use mode recognition means 41g for referring to area use mode map information representing correspondences between the second identification information and type information representing types of use modes of the divided areas, and recognizing the type of use mode of the divided area where the user is, according to the second identification information and first identification information.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Acute kidney injury (AKI) transformed to chronic kidney disease (CKD) is a critical clinical issue characterized by tubulointerstitial inflammation (TII) and fibrosis. However, the exact mechanism remains largely unclear. In this study, we used single-cell RNA sequencing (scRNA-seq) to obtain a high-resolution profile of T cells in AKI to CKD transition with a mice model of unilateral ischemia-reperfusion injury (uIRI). We found that T cells accumulated increasingly with the progression of AKI to CKD, which was categorized into 9 clusters. A notably increased proportion of CD8 T cells via self-proliferation occurred in the early stage of AKI was identified. Further study revealed that the CD8 T cells were recruited through CXCL16-CXCR6 pathway mediated by macrophages. Notably, CD8 T cells induced endothelial cell apoptosis via Fas ligand-Fas signaling. Consistently, increased CD8 T cell infiltration accompanied with peritubular capillaries (PTCs) rarefaction was observed in uIRI mice. More impressively, the loss of PTCs and renal fibrosis was remarkably ameliorated after the elimination of CD8 T cells. In summary, our study provides a novel insight into the role of CD8 T cells in the transition from AKI to CKD via induction of PTCs rarefaction, which could suggest a promising therapeutic target for AKI.
Part 1: The first 3 patients selected for the study will be treated with the active drug in an open-label manner at intervals of 1 week and will have weekly clinic visits until Day 14, after which the visit will be every two weeks. When the first 3 patients have completed two weeks of treatment and the safety and tolerability data has been reviewed by the PI and an independent clinician, provided the data is favourable the randomisation process will begin (Part 2). The first 3 patients will continue treatment for a total of 8 weeks and will be assessed throughout the trial by the Principal Investigator according to the Schedule of Events Part 2: Sixteen patients will be randomised 1:1. between active and placebo and patients allocated to either group will receive the appropriate product throughout the trial.